NASDAQ · Financial Statements
Avadel Pharmaceuticals plc (AVDL) Financial Statements
$21.64
NASDAQ: AVDL
Market Cap $2.12B
Overview Financials Dividend Avadel Pharmaceuticals plc most recently reported annual revenue of $169.0M, net profit of $-49.0M, revenue has compounded at 23.4% a year over the last five years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2020 2021 2022 2023 2024 Revenue $22.0M $0 $0 $28.0M $169.0M Operating Profit $6.0M $-86.0M $-99.0M $-138.0M $-42.0M Net Profit $7.0M $-77.0M $-137.0M $-160.0M $-49.0M EPS $0.13 $-1.32 $-2.29 $-2.00 $-0.51 Op Margin 26.0% — — -493.0% -25.1%
Balance Sheet (USD)
Metric 2020 2021 2022 2023 2024 Total Assets $312.0M $247.0M $133.0M $165.0M $164.0M Total Liabilities $149.0M $169.0M $154.0M $77.0M $90.0M Cash $72.0M $51.0M $74.0M $31.0M $51.0M Borrowings $131.0M $145.0M $131.0M $3.0M $2.0M
Cash Flow (USD)
Metric 2020 2021 2022 2023 2024 Operating Cash Flow $-49.0M $-77.0M $-70.0M $-129.0M $-47.0M Investing Cash Flow $-70.0M $57.0M $79.0M $-50.0M $52.0M Financing Cash Flow $0 $0 $-11.0M $28.0M $7.0M Net Cash Flow $62.0M $-21.0M $23.0M $-43.0M $20.0M Free Cash Flow $-49.0M $-77.0M $-71.0M $-129.0M $-47.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.66 EV / EBITDA 177.56 FCF Yield 1.30% Quick Ratio 2.37 Interest Coverage 1.12 Return 1Y — Return 3Y — Return 5Y —
Screens featuring this stock